Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen.

AIDS research and human retroviruses - 1 Jun 2005

Gianotti Nicola, Seminari Elena, Lazzarin Adriano, Boeri Enzo, Clementi Massimo, Danise Anna, Salpietro Stefania, Fusetti Giuliana, Castagna Antonella

Abstract excerpt

The redistribution of mutations related to protease inhibitor (PI) resistance after a PI-sparing regimen in human immunodeficiency virus (HIV)-infected, highly PI-experienced patients was prospectively assessed. Twenty-five patients failing a PI-including regimen were given PI-sparing antiretroviral therapy, and then followed for 24 weeks after PI resumption. Genotyping was performed by direct sequencing before...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Drug Resistance, Viral

Share to Drug Therapy, Combination

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 15989459
DOI: 10.1089/aid.2005.21.545

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen.PMID 15989459Read ↗

Navigating HIV-1 drug resistance: A comprehensive review of protease inhibitor efficacy and mutation dynamics.Semantic proximity Read ↗

Resistance to protease inhibitors.Semantic proximity Read ↗

Fitness Cost of Antiretroviral Drug Resistance Mutations on the pol Gene during Analytical Antiretroviral Treatment Interruption among Individuals Experiencing Virological FailureSemantic proximity Read ↗

HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance.Semantic proximity Read ↗

Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.Semantic proximity Read ↗

Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.Semantic proximity Read ↗

Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors.Semantic proximity Read ↗

Class-sparing regimens for initial treatment of HIV-1 infection.Semantic proximity Read ↗

Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection.Semantic proximity Read ↗

Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.Semantic proximity Read ↗

Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.Semantic proximity Read ↗

Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.